SCHEMBL3279060

SCHEMBL3279060

O=C(C=Cc1ccc2ccccc2c1)Nc1ccccc1-c1nnn[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.47
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
MMP1 P03956 6/20 0.44
MMP2 P08253 6/20 0.44
MMP9 P14780 6/20 0.44
HDAC4 P56524 2/20 0.42
EP300 Q09472 1/20 0.42
MEF2D Q14814 1/20 0.42
HDAC1 Q13547 2/20 0.42
TRPM2 O94759 1/20 0.40
LTB4R Q15722 1/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
ALDH1A1 P00352 2/20 0.40
TP53 P04637 2/20 0.40
CYP3A4 P08684 2/20 0.40
HPGD P15428 2/20 0.40
HIF1A Q16665 2/20 0.40
NPC1 O15118 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3279047 1.00 HCAR2 (0.47) HCAR2MAOAMAOBMMP1MMP2
SCHEMBL3273683 0.89 PTPN1 (0.45) HCAR2MAOAMAOBMMP1MMP2
SCHEMBL3272673 0.89 EGFR (0.44) HCAR2MAOAMAOBMMP1MMP2
SCHEMBL3273681 0.89 PTPN1 (0.45) HCAR2MAOAMAOBMMP1MMP2
SCHEMBL3273782 0.89 EGFR (0.47) HCAR2MAOAMAOBMMP1MMP2
SCHEMBL3272677 0.89 EGFR (0.44) HCAR2MAOAMAOBMMP1MMP2
SCHEMBL3273777 0.89 EGFR (0.47) HCAR2MAOAMAOBMMP1MMP2
SCHEMBL16272297 0.86 MMP1 (0.48) MMP1MMP2MMP9TRPM2LTB4R
SCHEMBL13320677 0.83 MEN1 (0.62) MMP1MMP2MMP9LTB4RMEN1
SCHEMBL6784145 0.79 TERT (0.61) LTB4RALDH1A1TP53NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087496-A1 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-04-08 US claimed
US-20100087496-A1 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-04-08 US disclosed
EP-2121569-A2 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2009-11-25 EP disclosed
WO-2008074755-A2 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087496-A1 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS TRPV1, TRPA1, TRPM8 HCAR2 180/4885MAOA 3704/4885MAOB 3995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.